ACM
BCAX

ADAR1 Capital Management’s Bicara Therapeutics BCAX Stock Holding History

ADAR1 Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Hold
13,705
– – 0.02% 246
2025
Q4 		$231K Hold
13,705
– – 0.02% 226
2025
Q3 		$216K Sell
13,705
-9,170
-40% -$103K 0.02% 178
2025
Q2 		$213K Buy
+22,875
New +$273K 0.03% 154
2024
Q4 		– Sell
-40,440
Closed -$1.03M – 316
2024
Q3 		$1.03M Buy
+40,440
New +$1.03M 0.17% 75

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

ADAR1 Capital Management's BCAX Position: Q1 2026 in Review

ADAR1 Capital Management held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 13,705 shares worth $273K. The position accounts for 0.02% of the portfolio, ranked #246.

ADAR1 Capital Management first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.03M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • ADAR1 Capital Management held 13,705 shares of Bicara Therapeutics worth $273K as of Q1 2026.
  • ADAR1 Capital Management left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q1 2026, its #246 holding.
  • ADAR1 Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • ADAR1 Capital Management's Bicara Therapeutics position peaked at $1.03M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.